{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:56:59Z","timestamp":1792789019681,"version":"4.5.0"},"reference-count":204,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2018-12365790"],"award-info":[{"award-number":["RF-2018-12365790"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PE-2016-02362756"],"award-info":[{"award-number":["PE-2016-02362756"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["IG-21687"],"award-info":[{"award-number":["IG-21687"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondazione Italiana Linfomi","award":["Bando giovani ricercatori 2020"],"award-info":[{"award-number":["Bando giovani ricercatori 2020"]}]},{"DOI":"10.13039\/501100004710","name":"Fondazione Umberto Veronesi","doi-asserted-by":"publisher","award":["Post-doctoral Fellowships-year 2021"],"award-info":[{"award-number":["Post-doctoral Fellowships-year 2021"]}],"id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>KRAS mutations account for the most frequent mutations in human cancers, and are generally correlated with disease aggressiveness, poor prognosis, and poor response to therapies. KRAS is required for adult hematopoiesis and plays a key role in B cell development and mature B cell proliferation and survival, proved to be critical for B cell receptor-induced ERK pathway activation. In mature B cell neoplasms, commonly seen in adults, KRAS and RAS-MAPK pathway aberrations occur in a relevant fraction of patients, reaching high recurrence in some specific subtypes like multiple myeloma and hairy cell leukemia. As inhibitors targeting the RAS-MAPK pathway are being developed and improved, it is of outmost importance to precisely identify all subgroups of patients that could potentially benefit from their use. Herein, we review the role of KRAS and RAS-MAPK signaling in malignant hematopoiesis, focusing on mature B cell lymphoproliferative disorders. We discuss KRAS and RAS-MAPK pathway aberrations describing type, incidence, mutual exclusion with other genetic abnormalities, and association with prognosis. We review the current therapeutic strategies applied in mature B cell neoplasms to counteract RAS-MAPK signaling in pre-clinical and clinical studies, including most promising combination therapies. We finally present an overview of genetically engineered mouse models bearing KRAS and RAS-MAPK pathway aberrations in the hematopoietic compartment, which are valuable tools in the understanding of cancer biology and etiology.<\/jats:p>","DOI":"10.3390\/cancers14030666","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T01:41:59Z","timestamp":1643420519000},"page":"666","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9705-7083","authenticated-orcid":false,"given":"Elena","family":"Vendramini","sequence":"first","affiliation":[{"name":"Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8746-9404","authenticated-orcid":false,"given":"Riccardo","family":"Bomben","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pozzo","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Bittolo","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Tissino","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valter","family":"Gattei","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Zucchetto","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Uprety, D., and Adjei, A.A. (2020). KRAS: From undruggable to a druggable Cancer Target. Cancer Treat. Rev., 89.","DOI":"10.1016\/j.ctrv.2020.102070"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1084\/jem.170.5.1715","article-title":"Ras oncogene mutation in multiple myeloma","volume":"170","author":"Neri","year":"1989","journal-title":"J. Exp. Med."},{"key":"ref_3","first-page":"665","article-title":"Drug resistance in targeted cancer therapies with RAF inhibitors","volume":"4","author":"Degirmenci","year":"2021","journal-title":"Cancer Drug Resist."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Cuesta, C., Arevalo-Alameda, C., and Castellano, E. (2021). The Importance of Being PI3K in the RAS Signaling Network. Genes, 12.","DOI":"10.3390\/genes12071094"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-981-15-3532-1_2","article-title":"B Cell Receptor Signaling","volume":"1254","author":"Tanaka","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1091\/mbc.E18-09-0560","article-title":"Multiple sources of signal amplification within the B-cell Ras\/MAPK pathway","volume":"30","author":"McLaurin","year":"2019","journal-title":"Mol. Biol. Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev-immunol-020711-075027","article-title":"Pathogenesis of human B cell lymphomas","volume":"30","author":"Shaffer","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nri3814","article-title":"Germinal centres and B cell lymphomagenesis","volume":"15","author":"Basso","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood.2020005289","article-title":"Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes","volume":"136","author":"Nadeu","year":"2020","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"38180","DOI":"10.18632\/oncotarget.9500","article-title":"Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15567","article-title":"Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib","volume":"183","author":"Jain","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.1121343109","article-title":"Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing","volume":"109","author":"Lohr","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1182\/blood-2015-12-682591","article-title":"Pediatric-type nodal follicular lymphoma: A Biologically distinct lymphoma with frequent MAPK pathway mutations","volume":"128","author":"Louissaint","year":"2016","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/ng.2468","article-title":"The genetic landscape of mutations in Burkitt lymphoma","volume":"44","author":"Love","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1182\/blood-2018-09-871418","article-title":"Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma","volume":"133","author":"Grande","year":"2019","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature11378","article-title":"Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics","volume":"490","author":"Schmitz","year":"2012","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/ng.2469","article-title":"Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing","volume":"44","author":"Richter","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2017-11-814913","article-title":"Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma","volume":"131","author":"Tiacci","year":"2018","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"20928","DOI":"10.18632\/oncotarget.25037","article-title":"Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations","volume":"9","author":"Greil","year":"2018","journal-title":"Oncotarget"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature14666","article-title":"Non-coding recurrent mutations in chronic lymphocytic leukaemia","volume":"526","author":"Puente","year":"2015","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/blood-2016-01-691550","article-title":"Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy","volume":"128","author":"Herling","year":"2016","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood-2017-11-817296","article-title":"Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide","volume":"131","author":"Takahashi","year":"2018","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3324\/haematol.2018.196931","article-title":"Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia","volume":"104","author":"Gimenez","year":"2019","journal-title":"Haematologica"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/s41375-019-0444-6","article-title":"KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival","volume":"33","author":"Vendramini","year":"2019","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/leu.2017.291","article-title":"Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia","volume":"32","author":"Nadeu","year":"2018","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/ng.2828","article-title":"High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias","volume":"46","author":"Waterfall","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood-2017-01-765107","article-title":"Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations","volume":"130","author":"Durham","year":"2017","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/bjh.12735","article-title":"Alternative BRAF mutations in BRAF V600E-negative hairy cell leukaemias","volume":"165","author":"Tschernitz","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1158\/1078-0432.CCR-14-2759","article-title":"Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing","volume":"21","author":"Parry","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1084\/jem.20120904","article-title":"The coding genome of splenic marginal zone lymphoma: Activation of NOTCH2 and other pathways regulating marginal zone development","volume":"209","author":"Rossi","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3324\/haematol.2016.160192","article-title":"Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma","volume":"102","author":"Jallades","year":"2017","journal-title":"Haematologica"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"10444","DOI":"10.1038\/s41598-019-46906-1","article-title":"Systematic Review of Somatic Mutations in Splenic Marginal Zone Lymphoma","volume":"9","author":"Parker","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1038\/s41375-018-0082-4","article-title":"High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations","volume":"32","author":"Pillonel","year":"2018","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/s41379-018-0064-0","article-title":"Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement","volume":"31","author":"Hyeon","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e558","DOI":"10.3324\/haematol.2018.214957","article-title":"Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses","volume":"104","author":"Cascione","year":"2019","journal-title":"Haematologica"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/PAS.0000000000000523","article-title":"NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease","volume":"40","author":"Martinez","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.leukres.2011.12.015","article-title":"Incidence of the BRAF V600E mutation in chronic lymphocytic leukaemia and prolymphocytic leukaemia","volume":"36","author":"Langabeer","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: Implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1038\/oncsis.2017.36","article-title":"Molecular signaling in multiple myeloma: Association of RAS\/RAF mutations and MEK\/ERK pathway activation","volume":"6","author":"Xu","year":"2017","journal-title":"Oncogenesis"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2643-3230.BCD-20-0051","article-title":"Genomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK-STAT pathway","volume":"1","author":"Liu","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"ref_50","first-page":"2682","article-title":"MAP-kinase and JAK-STAT pathways dysregulation in plasmablastic lymphoma","volume":"10","author":"Nicolae","year":"2021","journal-title":"Haematologica"},{"key":"ref_51","first-page":"1120","article-title":"Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma","volume":"106","author":"Loghavi","year":"2021","journal-title":"Haematologica"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1038\/s41467-021-25405-w","article-title":"Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma","volume":"12","author":"Frontzek","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.hoc.2020.05.002","article-title":"Molecular Pathogenesis of Mantle Cell Lymphoma","volume":"34","author":"Navarro","year":"2020","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","article-title":"Molecular pathogenesis of mantle cell lymphoma","volume":"122","author":"Jares","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","article-title":"Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features","volume":"72","author":"Navarro","year":"2012","journal-title":"Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-11-764332","article-title":"Genetics of diffuse large B-cell lymphoma","volume":"131","author":"Pasqualucci","year":"2018","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ccr.2010.10.030","article-title":"BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma","volume":"18","author":"Mandelbaum","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"12420","DOI":"10.1073\/pnas.1305656110","article-title":"PTEN loss defines a PI3K\/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma","volume":"110","author":"Pfeifer","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nature13765","article-title":"Loss of signalling via Galpha13 in germinal centre B-cell-derived lymphoma","volume":"516","author":"Muppidi","year":"2014","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0002-9440(10)63284-1","article-title":"BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma","volume":"165","author":"Iqbal","year":"2004","journal-title":"Am. J. Pathol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41408-018-0089-0","article-title":"Integrated DNA\/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay","volume":"8","author":"Intlekofer","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/(SICI)1097-0215(19970502)71:3<364::AID-IJC10>3.0.CO;2-G","article-title":"A one-step DGGE scanning method for detection of mutations in the K-, N-, and H-ras oncogenes: Mutations at codons 12, 13 and 61 are rare in B-cell non-Hodgkin\u2019s lymphoma","volume":"71","author":"Nedergaard","year":"1997","journal-title":"Int. J. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1158\/1541-7786.MCR-18-0582","article-title":"Sleeping Beauty Screen Identifies RREB1 and Other Genetic Drivers in Human B-cell Lymphoma","volume":"17","author":"Rahrmann","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1210\/jc.2014-3250","article-title":"Oncogenic mutations and chromosomal aberrations in primary extranodal diffuse large B-cell lymphomas of the thyroid--a study of 21 cases","volume":"100","author":"Knief","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/modpathol.2012.73","article-title":"Thyroid carcinoma-associated genetic mutations also occur in thyroid lymphomas","volume":"25","author":"Aggarwal","year":"2012","journal-title":"Mod. Pathol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/bs.ai.2021.05.002","article-title":"Follicular lymphoma dynamics","volume":"150","author":"Milpied","year":"2021","journal-title":"Adv. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: A retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","article-title":"Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation","volume":"112","author":"Green","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41379-020-00673-x","article-title":"The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy","volume":"34","author":"Egan","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00428-019-02691-w","article-title":"Subsequent development of histiocytic sarcoma and follicular lymphoma: Cytogenetics and next-generation sequencing analyses provide evidence for transdifferentiation of early common lymphoid precursor-a case report and review of literature","volume":"476","author":"Pericart","year":"2020","journal-title":"Virchows Arch."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"7259","DOI":"10.1073\/pnas.1137463100","article-title":"Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy","volume":"100","author":"Jenson","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood-2017-03-776278","article-title":"Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation","volume":"130","author":"Schmidt","year":"2017","journal-title":"Blood"},{"key":"ref_79","first-page":"11","article-title":"Burkitt lymphoma in adolescents and young adults: Management challenges","volume":"8","author":"Dozzo","year":"2017","journal-title":"Adolesc. Health Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S0140-6736(11)61177-X","article-title":"Burkitt\u2019s lymphoma","volume":"379","author":"Molyneux","year":"2012","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"100855","DOI":"10.1016\/j.tranon.2020.100855","article-title":"Identification of clinical molecular targets for childhood Burkitt lymphoma","volume":"13","author":"Zhang","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2018-03-842088","article-title":"IG-MYC (+) neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas","volume":"132","author":"Wagener","year":"2018","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/j.seminhematol.2016.05.007","article-title":"Hodgkin lymphoma: Pathology and Biology","volume":"53","author":"Mathas","year":"2016","journal-title":"Semin. Hematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrc2542","article-title":"The biology of Hodgkin\u2019s lymphoma","volume":"9","author":"Kuppers","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"125","author":"Reichel","year":"2015","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1182\/bloodadvances.2019001012","article-title":"Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion","volume":"3","author":"Wienand","year":"2019","journal-title":"Blood Adv."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2643-3230.BCD-20-0203","article-title":"Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients","volume":"2","author":"Venanzi","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e865","DOI":"10.1016\/j.clml.2021.06.012","article-title":"Primary Mediastinal B-Cell Lymphoma: A 2021 Update on Genetics, Diagnosis, and Novel Therapeutics","volume":"21","author":"Ahmed","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1182\/blood.2019002067","article-title":"Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade","volume":"134","author":"Chapuy","year":"2019","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.2019001126","article-title":"Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma","volume":"134","author":"Mottok","year":"2019","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrc.2016.8","article-title":"The molecular pathogenesis of chronic lymphocytic leukaemia","volume":"16","author":"Fabbri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Tadmor, T., and Levy, I. (2021). Richter Transformation in Chronic Lymphocytic Leukemia: Update in the Era of Novel Agents. Cancers, 13.","DOI":"10.3390\/cancers13205141"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood-2015-02-585042","article-title":"Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia","volume":"126","author":"Guieze","year":"2015","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/leu.2016.88","article-title":"CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia","volume":"30","author":"Bulian","year":"2016","journal-title":"Leukemia"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2013.50.8515","article-title":"CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia","volume":"32","author":"Bulian","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41375-018-0215-9","article-title":"Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia","volume":"33","author":"Leeksma","year":"2019","journal-title":"Leukemia"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/bjh.13291","article-title":"BRAF(V600E) mutations are found in Richter syndrome and may allow targeted therapy in a subset of patients","volume":"170","author":"Sellar","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/gcc.22650","article-title":"Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group","volume":"57","author":"Chevret","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2011.060129","article-title":"NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL","volume":"97","author":"Rossi","year":"2012","journal-title":"Haematologica"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41467-018-03170-7","article-title":"Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia","volume":"9","author":"Herling","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"6217","DOI":"10.1158\/1078-0432.CCR-15-2903","article-title":"Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia","volume":"22","author":"Pandzic","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood.2020006765","article-title":"Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia","volume":"138","author":"Murali","year":"2021","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1200\/JCO.2016.71.1556","article-title":"Genomics of Hairy Cell Leukemia","volume":"35","author":"Tiacci","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.blre.2014.06.003","article-title":"Hairy cell leukemia: Update on molecular profiling and therapeutic advances","volume":"28","author":"Grever","year":"2014","journal-title":"Blood Rev."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3324\/haematol.2012.078071","article-title":"Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia","volume":"98","author":"Tiacci","year":"2013","journal-title":"Haematologica"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1038\/sj.onc.1206398","article-title":"Regulation of hairy-cell survival through constitutive activation of mitogen-activated protein kinase pathways","volume":"22","author":"Kamiguti","year":"2003","journal-title":"Oncogene"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2014-10-603100","article-title":"BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity","volume":"125","author":"Pettirossi","year":"2015","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2011-09-379339","article-title":"Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation","volume":"119","author":"Xi","year":"2012","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Weston-Bell, N.J., Tapper, W., Gibson, J., Bryant, D., Moreno, Y., John, M., Ennis, S., Kluin-Nelemans, H.C., Collins, A.R., and Sahota, S.S. (2016). Exome Sequencing in Classic Hairy Cell Leukaemia Reveals Widespread Variation in Acquired Somatic Mutations between Individual Tumours Apart from the Signature BRAF V(600)E Lesion. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0149162"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2015-04-643361","article-title":"Recurrent CDKN1B (p27) mutations in hairy cell leukemia","volume":"126","author":"Dietrich","year":"2015","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.beha.2016.09.004","article-title":"Molecular pathogenesis of splenic and nodal marginal zone lymphoma","volume":"30","author":"Spina","year":"2017","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1182\/blood-2016-02-696757","article-title":"The genetics of nodal marginal zone lymphoma","volume":"128","author":"Spina","year":"2016","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.beha.2016.09.002","article-title":"MALT lymphoma: Genetic abnormalities, Immunol.ogical stimulation and molecular mechanism","volume":"30","author":"Du","year":"2017","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.beha.2019.06.001","article-title":"B and T cell prolymphocytic leukaemia","volume":"32","author":"Cross","year":"2019","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11912-017-0581-x","article-title":"Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment","volume":"19","author":"Collignon","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"ref_116","first-page":"1821","article-title":"Genetic characterization of B-cell prolymphocytic leukemia: A prognostic model involving MYC and TP53","volume":"134","author":"Chapiro","year":"2019","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.19.02314","article-title":"Genomic Landscape of Waldenstrom Macroglobulinemia and Its Impact on Treatment Strategies","volume":"38","author":"Treon","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.2016.71.0814","article-title":"Genomics, Signaling, and Treatment of Waldenstrom Macroglobulinemia","volume":"35","author":"Hunter","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.beha.2016.08.024","article-title":"Origin of Waldenstrom\u2019s macroglobulinaemia","volume":"29","author":"Jimenez","year":"2016","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstrom\u2019s macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1182\/bloodadvances.2018022962","article-title":"Insights into the genomic landscape of MYD88 wild-type Waldenstrom macroglobulinemia","volume":"2","author":"Hunter","year":"2018","journal-title":"Blood Adv."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1158\/2159-8290.CD-18-0873","article-title":"A recurrent Activating Missense Mutation in Waldenstrom Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation","volume":"9","author":"Decaudin","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Awada, H., Thapa, B., Awada, H., Dong, J., Gurnari, C., Hari, P., and Dhakal, B. (2021). A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics. Cells, 10.","DOI":"10.3390\/cells10081961"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1038\/s41375-018-0103-3","article-title":"Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms","volume":"32","author":"Hoang","year":"2018","journal-title":"Leukemia"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1158\/1078-0432.CCR-19-1507","article-title":"BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma","volume":"26","author":"Boyle","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1038\/s41375-018-0108-y","article-title":"Kinase domain activation through gene rearrangement in multiple myeloma","volume":"32","author":"Morgan","year":"2018","journal-title":"Leukemia"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/leu.2008.259","article-title":"Bone marrow microenvironment and the identification of new targets for myeloma therapy","volume":"23","author":"Podar","year":"2009","journal-title":"Leukemia"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41467-020-20524-2","article-title":"The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma","volume":"12","author":"Boyle","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","article-title":"Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes","volume":"128","author":"Kortum","year":"2016","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1158\/0008-5472.CAN-17-3115","article-title":"From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells","volume":"78","author":"Spaan","year":"2018","journal-title":"Cancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2013-05-504340","article-title":"Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy","volume":"123","author":"Mulligan","year":"2014","journal-title":"Blood"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Leeman-Neill, R.J., Soderquist, C.R., Montanari, F., Raciti, P., Park, D., Radeski, D., Mansukhani, M.M., Murty, V.V., Hsiao, S., and Alobeid, B. (Haematologica, 2020). Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas, Haematologica, online ahead of print.","DOI":"10.3324\/haematol.2020.267294"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1182\/blood-2018-03-791426","article-title":"Biology and management of primary effusion lymphoma","volume":"132","author":"Shimada","year":"2018","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/(SICI)1098-2264(199901)24:1<16::AID-GCC3>3.0.CO;2-F","article-title":"Genetic characterization of HHV-8\/KSHV-positive primary effusion lymphoma reveals frequent mutations of BCL6: Implications for disease pathogenesis and histogenesis","volume":"24","author":"Gaidano","year":"1999","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1182\/blood-2010-12-323659","article-title":"Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines","volume":"118","author":"Roy","year":"2011","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/leu.2015.22","article-title":"Analysis of mutational signatures in exomes from B-cell lymphoma cell lines suggest APOBEC3 family members to be involved in the pathogenesis of primary effusion lymphoma","volume":"29","author":"Wagener","year":"2015","journal-title":"Leukemia"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Calvani, J., Gerard, L., Fadlallah, J., Poullot, E., Galicier, L., Robe, C., Garzaro, M., Bertinchamp, R., Boutboul, D., and Cuccuini, W. (2021). A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients. Am. J. Surg. Pathol.","DOI":"10.1097\/PAS.0000000000001813"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJMoa1506583","article-title":"Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia","volume":"373","author":"Tiacci","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMc1202124","article-title":"BRAF inhibition in refractory hairy-cell leukemia","volume":"366","author":"Dietrich","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_142","first-page":"PO.18.00070","article-title":"Vemurafenib in Patients with Relapsed Refractory Multiple Myeloma Harboring BRAF (V600) Mutations: A Cohort of the Histology-Independent VE-BASKET Study","volume":"2","author":"Raje","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1158\/2159-8290.CD-13-0014","article-title":"Targeting the BRAF V600E mutation in multiple myeloma","volume":"3","author":"Andrulis","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1182\/blood-2015-12-686782","article-title":"Spatially divergent clonal evolution in multiple myeloma: Overcoming resistance to BRAF inhibition","volume":"127","author":"Raab","year":"2016","journal-title":"Blood"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/j.clml.2014.06.004","article-title":"Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma","volume":"14","author":"Sharman","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.clml.2013.12.003","article-title":"BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation","volume":"14","author":"Bohn","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41375-018-0270-2","article-title":"Targeting MEK in vemurafenib-resistant hairy cell leukemia","volume":"33","author":"Caeser","year":"2019","journal-title":"Leukemia"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/hon.2353","article-title":"Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation","volume":"35","author":"Mey","year":"2017","journal-title":"Hematol. Oncol."},{"key":"ref_149","first-page":"8821415","article-title":"Rapid Response in a Patient with Relapsed\/Refractory Multiple Myeloma Treated with BRAF\/MEK Inhibitors","volume":"2020","author":"Otieno","year":"2020","journal-title":"Case Rep. Hematol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa2031298","article-title":"Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia","volume":"384","author":"Tiacci","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1038\/s41375-021-01210-8","article-title":"Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: A pilot phase-2 clinical trial","volume":"35","author":"Tiacci","year":"2021","journal-title":"Leukemia"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2018-99-113135","article-title":"Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent\/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)","volume":"132","author":"Kreitman","year":"2018","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.18632\/oncotarget.27775","article-title":"Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma","volume":"11","author":"Suzuki","year":"2020","journal-title":"Oncotarget"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/cam4.276","article-title":"A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434","volume":"3","author":"Srkalovic","year":"2014","journal-title":"Cancer Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/hon.2043","article-title":"Sorafenib in patients with refractory or recurrent multiple myeloma","volume":"31","author":"Yordanova","year":"2013","journal-title":"Hematol. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1182\/blood-2010-04-282400","article-title":"Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib","volume":"117","author":"Messmer","year":"2011","journal-title":"Blood"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/leu.2011.2","article-title":"Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1","volume":"25","author":"Huber","year":"2011","journal-title":"Leukemia"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2119\/molmed.2011.00164","article-title":"Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1)","volume":"18","author":"Fecteau","year":"2012","journal-title":"Mol. Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/leu.2011.364","article-title":"Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells","volume":"26","author":"Rosich","year":"2012","journal-title":"Leukemia"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1756-8722-6-46","article-title":"A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: An eastern cooperative oncology group study (E1404)","volume":"6","author":"Greenwald","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1365-2141.2012.09139.x","article-title":"Phase II study of sorafenib in patients with relapsed or refractory lymphoma","volume":"158","author":"Guidetti","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.leukres.2009.07.013","article-title":"Inhibition of MEK\/ERK1\/2 sensitizes lymphoma cells to sorafenib-induced apoptosis","volume":"34","author":"Nguyen","year":"2010","journal-title":"Leuk. Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2141.2011.08685.x","article-title":"BAY 43-9006\/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines","volume":"155","author":"Ullrich","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1158\/1535-7163.MCT-12-0532","article-title":"Induction of endoplasmic reticulum stress by sorafenib and activation of NF-kappaB by lestaurtinib as a novel resistance mechanism in Hodgkin lymphoma cell lines","volume":"12","author":"Holz","year":"2013","journal-title":"Mol. Cancer"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/1078-0432.CCR-12-1935","article-title":"Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma","volume":"19","author":"Montraveta","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ajh.22263","article-title":"Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin","volume":"87","author":"Ramakrishnan","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2014.81","article-title":"BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts","volume":"28","author":"Locatelli","year":"2014","journal-title":"Leukemia"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1038\/leu.2013.28","article-title":"Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD\/SCID mice with Hodgkin lymphoma cell line xenografts","volume":"27","author":"Locatelli","year":"2013","journal-title":"Leukemia"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.1158\/1078-0432.CCR-14-0770","article-title":"Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases","volume":"20","author":"Guidetti","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1182\/blood.2020010572","article-title":"Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited anti-tumor activity","volume":"138","author":"Sacco","year":"2021","journal-title":"Blood"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S1470-2045(20)30464-2","article-title":"Intermittent schedules of the oral RAF-MEK inhibitor CH5126766\/VS-6766 in patients with RAS\/RAF-mutant solid tumours and multiple myeloma: A single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study","volume":"21","author":"Guo","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1080\/10428194.2017.1365853","article-title":"Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia","volume":"59","author":"Andritsos","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/leu.2015.208","article-title":"Inhibiting MEK in MAPK pathway-activated myeloma","volume":"30","author":"Heuck","year":"2016","journal-title":"Leukemia"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"20004","DOI":"10.1073\/pnas.2005052117","article-title":"Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma","volume":"117","author":"Shirazi","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Kozaki, R., Vogler, M., Walter, H.S., Jayne, S., Dinsdale, D., Siebert, R., Dyer, M.J.S., and Yoshizawa, T. (2018). Responses to the Selective Bruton\u2019s Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO\/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines. Cancers, 10.","DOI":"10.3390\/cancers10040127"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-135845","article-title":"Safety and Preliminary Efficacy Results from a Phase Ib\/II Study of Cobimetinib As a Single Agent and in Combination with Venetoclax with or without Atezolizumab in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Schjesvold","year":"2020","journal-title":"Blood"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bjh.15282","article-title":"MEK1\/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment","volume":"182","author":"Crassini","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1080\/10428194.2018.1542148","article-title":"Dual inhibition of MEK1\/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment","volume":"60","author":"Shen","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1158\/1078-0432.CCR-15-1076","article-title":"A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1\/2 Inhibitor, in Relapsed\/Refractory Multiple Myeloma","volume":"22","author":"Holkova","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/bjh.14544","article-title":"University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL","volume":"181","author":"Galanina","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1182\/blood-2011-03-340109","article-title":"The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma","volume":"118","author":"Bhalla","year":"2011","journal-title":"Blood"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.3324\/haematol.2018.211110","article-title":"Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma","volume":"104","author":"Ramakrishnan","year":"2019","journal-title":"Haematologica"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/annonc\/mdw131","article-title":"Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas","volume":"27","author":"Gaudio","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1182\/blood-2002-11-3507","article-title":"MEK\/ERK pathway is aberrantly active in Hodgkin disease: A signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival","volume":"102","author":"Zheng","year":"2003","journal-title":"Blood"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"35745","DOI":"10.1038\/srep35745","article-title":"Dual PI3K\/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation","volume":"6","author":"Locatelli","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.phrs.2018.08.013","article-title":"Targeting oncogenic Raf protein-serine\/threonine kinases in human cancers","volume":"135","author":"Roskoski","year":"2018","journal-title":"Pharm. Res."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"16639","DOI":"10.1074\/jbc.M200360200","article-title":"NF-kappa B as a therapeutic target in multiple myeloma","volume":"277","author":"Hideshima","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/blood-2015-11-680074","article-title":"BRAF inhibition in hairy cell leukemia with low-dose vemurafenib","volume":"127","author":"Dietrich","year":"2016","journal-title":"Blood"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1172\/JCI93801","article-title":"Drug-perturbation-based stratification of blood cancer","volume":"128","author":"Dietrich","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1002\/cam4.3136","article-title":"Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma","volume":"9","author":"Tsukamoto","year":"2020","journal-title":"Cancer Med."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1535-6108(04)00085-6","article-title":"Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects","volume":"5","author":"Tuveson","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1182\/blood-2008-03-147587","article-title":"K-RasG12D-induced T-cell lymphoblastic lymphoma\/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors","volume":"112","author":"Kindler","year":"2008","journal-title":"Blood"},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Mullins, C.D., Su, M.Y., Hucthagowder, V., Chu, L., Lu, L., Kulkarni, S., Novack, D., Vij, R., and Tomasson, M.H. (2013). Germinal center B-cells resist transformation by Kras independently of tumor suppressor Arf. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0067941"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1158\/2159-8290.CD-18-1220","article-title":"Tissue-Specific Oncogenic Activity of KRAS(A146T)","volume":"9","author":"Poulin","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"16395","DOI":"10.1073\/pnas.1418126111","article-title":"K-RasV14I recapitulates Noonan syndrome in mice","volume":"111","author":"Fabbiano","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2010-12-326058","article-title":"Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1182\/blood-2010-04-281527","article-title":"Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic\/monocytic precursors in a murine model of chronic myelomonocytic leukemia","volume":"116","author":"Wang","year":"2010","journal-title":"Blood"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2020007156","article-title":"Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice","volume":"137","author":"Wen","year":"2021","journal-title":"Blood"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"11493","DOI":"10.1158\/0008-5472.CAN-05-2211","article-title":"Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts","volume":"65","author":"Mercer","year":"2005","journal-title":"Cancer Res."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"238ra71","DOI":"10.1126\/scitranslmed.3008004","article-title":"Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia","volume":"6","author":"Chung","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1182\/bloodadvances.2017006593","article-title":"BRAF(V600E) accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia","volume":"1","author":"Tsai","year":"2017","journal-title":"Blood Adv."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"18219","DOI":"10.1074\/jbc.M113.475376","article-title":"Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation","volume":"288","author":"Kong","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41375-018-0248-0","article-title":"Downregulating Notch counteracts Kras(G12D)-induced ERK activation and oxidative phosphorylation in myeloproliferative neoplasm","volume":"33","author":"Kong","year":"2019","journal-title":"Leukemia"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cell.2015.02.043","article-title":"The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo","volume":"161","author":"Karreth","year":"2015","journal-title":"Cell"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/666\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:09:58Z","timestamp":1760134198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":204,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cancers14030666"],"URL":"https:\/\/doi.org\/10.3390\/cancers14030666","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,28]]}}}